Suzhou HealGen Biopharma Completes Nearly RMB 100 Million Series A Initial Closing to Accelerate Innovation in mRNA Technology Platforms

Suzhou Huiyi Biomedical Technology Co., Ltd.Suzhou Huiyi Biomedical Technology Co., Ltd., established in 2021 and headquartered in Suzhou Industrial Park, is recognized as a Leading Enterprise and a Unicorn Cultivation Enterprise of Suzhou City. The company has undertaken provincial-level science and technology programs and serves as the Vice-President Unit of the First Council of the Nucleic Acid Drug Branch of the China Veterinary Drug Association. It has built a globally leading, independently owned intellectual property platform featuring a CLS/LNP “dual-wheel” delivery system, an mRNA design platform, and a manufacturing process platform. Leveraging this integrated platform, the company has developed a series of products including infectious disease vaccines, tumor vaccines, cell therapies, and protein replacement therapeutics.

During 2024, porcine PEDV and porcine deltacoronavirus (PDCoV) Breakthroughs have been successively achieved in the development of mRNA vaccines, with related findings published in top-tier international journals. In addition, several mRNA vaccines for economic animals developed by the company have been validated through field trials conducted by multiple end-users, and significant original breakthroughs have also been made in pet mRNA vaccines.

For this round of financing,Dr. Zhong Tianyi, Founder & CEOIndicates:“We sincerely appreciate the profound recognition and strong support from numerous distinguished investors in the industry, and we are even more grateful for the tireless efforts of all our team members. It is your trust and support that have enabled us to navigate the challenging yet opportunity-rich blue ocean of biomedicine. Huiyi Biomedical remains committed to technological innovation and industrialization in the mRNA field, providing superior options for human and animal health while addressing unmet clinical and market needs. With this round of financing, we aim to accelerate the clinical development and industrialization of our product pipeline, striving to become a globally competitive leader in the mRNA sector. We warmly welcome talented professionals at all levels across the industry to join Huiyi Biomedical and create brilliance together.”

Guozhong CapitalIndicates:“The mRNA therapeutics sector has demonstrated broad application prospects. With its leading technology, Huiyi Biomedical has emerged as an international leader in novel animal vaccine products. The delivery system independently developed by Huiyi Biomedical has overcome the ‘chokepoint’ patent barriers in the mRNA therapeutics field and maintains a lead across multiple pipelines within the industry. Currently, Huiyi Biomedical’s veterinary mRNA vaccines are on the verge of entering”IND Stage"Guozhong Capital is committed to providing long-term support for the development of domestic innovative pharmaceutical companies like Huiyi Biomedical, leveraging internationally leading innovative technologies to address clinical and market needs, and contributing to the healthy development of humans and animals."

VazymeIndicates:“Through our long-term collaboration with Huiyi Biomedical, we highly recognize its innovation and market competitiveness. As a leader in the field of mRNA vaccines, Huiyi Biomedical not only possesses a first-class R&D and production platform for nucleic acid drugs but also leads industry development with its forward-looking vision. We are pleased to support Huiyi Biomedical and work together to provide cost-optimized innovative veterinary mRNA vaccine solutions for agricultural development, dedicated to successfully bringing advanced vaccine products to the global market, enhancing the profitability of livestock customers, and promoting high-quality development in the pet industry.”

Guozhong Capital, established in December 2015, is a professional venture capital fund management platform founded by Dr. Shi Anping together with key core members from the former Shenzhen Capital Group (SCGC). The firm has a cumulative assets under management (AUM) of RMB 16 billion, comprising three entity funds under the National SME Development Fund and one direct-investment sub-fund under the National Green Development Fund. It is the first institution in China to consecutively manage three entity funds of the National SME Development Fund.

Guozhong Capital advocates an investment philosophy that prioritizes research and integrates investment with research, guiding investment decisions through in-depth industry chain analysis. It focuses on investment opportunities in strategic emerging industries, with particular emphasis on outstanding enterprises in the fields of healthcare and wellness, green low-carbon initiatives and new energy vehicles, semiconductors and electronic information, new materials and advanced manufacturing, AI+ and embodied intelligence, as well as next-generation displays and smart terminals. As of the end of 2024, Guozhong Capital had invested in over 210 companies, with a total investment amounting to nearly RMB 8 billion, and has established a relatively comprehensive layout across multiple industry chains, including new energy vehicles, intelligent driving, semiconductors and electronic components, biopharmaceuticals and healthcare, next-generation display technologies, robotics, and carbon fiber composites.

Vazyme is a biotechnology enterprise engaged in technological research and product development centered on functional proteins—such as enzymes, antigens, and antibodies—as well as high-molecular-weight organic materials. Leveraging its independently established key generic technology platforms, the company has successively expanded into the fields of life sciences, in vitro diagnostics, and biopharmaceuticals. As one of the few R&D-driven innovative enterprises in China that possess both autonomous and controllable upstream technology development capabilities and terminal product manufacturing capacities, Vazyme is committed to the intelligent manufacturing of “biochips,” continuously injecting new vitality into the development of the biotechnology industry.